BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Other Working Capital

Cash effect of changes in other operating assets and liabilities.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Other Working Capital · Q3 FY2026 · quarter ended Sep 2026

Other working capital turns positive

Q3 FY2026 other working capital was $7.92M, compared with -$19.85M a year earlier. Trailing-twelve-month other working capital was -$23.06M. Over 3 fiscal years it compounded at +134.7% a year.

Context

  • Other working capital amounted to 2.0% of revenue in FY2025, down 0.1 pp from a year earlier.
  • Other working capital grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other working capital holds near $7.92M or moves back toward the trailing-twelve-month quarterly average of -$5.77M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$7.92M+220.8% QoQ
Last fiscal yearDec 2025
-$65.97M+5.2% YoY
LTMSep 2026
-$23.06M-64.0% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+139.9%——
1 year+5.2%——
3-year CAGR+134.7%——
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
(65.97M) USD
Year-over-year change
-5.2%

Other Working Capital vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -64.0% is the 10th highest of 11, against a peer median of +147.7%.
  • Other working capital amounts to 0.0% of revenue for BMRN, versus a peer median of 4.2%.
BMRN Competitors
Other Working Capital for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$125.09M USD+5489.3%+83.8%17.5%
ASNDAscendis Pharma A/SLTM Sep 2026€113.79M EUR-7.5%+8.2%9.4%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$93.89M USD+126.0%+4.5%2.0%
INSMInsmed IncorporatedLTM Jun 2026$80.48M USD+252.0%+19.7%7.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$62.68M USD+262.6%+13.9%6.5%
VRTXVertex Pharmaceuticals IncorporatedLTM Jun 2026$46.8M USD-50.9%—0.4%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$42.44M USD+24575.6%+82.5%6.5%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$23.06M USD-64.0%+134.7%0.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$8.63M USD+169.3%—0.9%
PHARPharming Group N.V.LTM Mar 2026$1.54M USD+115.4%-54.0%0.4%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$1.52M USD-103.4%—0.2%
Peer median (excluding BMRN) —+147.7%+13.9%4.2%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.08M)141.56M167.65M426.86M348.9M
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
Deferred Income Tax(15.61M)(52.09M)(44.98M)56.1M48.74M
Stock-Based Compensation197.26M196.31M207.1M201.57M181.41M
Change in Working Capital66.03M(96.38M)(336.54M)(216.4M)(108.68M)
Accounts Receivables65.57M(82.03M)(190.44M)(57.91M)(228.05M)
Inventory(35.06M)(68.26M)(157.06M)(63.53M)119.21M
Accounts Payables15.69M59.02M68.85M(32.24M)66.14M
Other Working Capital19.83M(5.1M)(57.9M)(62.72M)(65.97M)
Other Non-Cash Items12.89M(115.47M)61.65M8.29M278.07M
Operating Cash Flow304.54M175.9M159.26M572.84M827.99M
Capital Expenditures(119.23M)(120.96M)(107.61M)(97.42M)(103.04M)
Acquisitions (Net)0000(285.19M)
Purchases of Investments(937.14M)(611.81M)(868.5M)(410.25M)(355.88M)
Sales of Investments691.05M620M864.86M633.02M337.8M
Other Investing Activities(24.64M)103.33M(10.92M)(853K)(7.94M)
Investing Cash Flow(366.31M)(20.03M)(111.24M)136.49M(414.24M)
Debt Repayment(3.04M)(2.61M)(2.29M)(494.99M)0
Common Stock Issued069.33M69.35M014.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.99M(85.38M)(85.79M)(31.46M)(56.85M)
Financing Cash Flow(48K)(18.65M)(18.73M)(526.45M)(42.39M)
Effect of Forex Changes(57K)32K1.31M4.83M(2.52M)
Net Change in Cash(61.88M)137.26M30.6M187.72M368.84M
Free Cash Flow185.31M54.94M51.65M475.42M724.96M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.